ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,289.82
0.17%
Dow Jones
38,686.32
1.51%
Gold vs US Dollar
2,331.155
0.16%
Brent Oil
81.145
0.42%
Bitcoin
69,120.57
2.03%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Lyra Therapeutics Inc (LYRA)

  7. Lyra Therapeutics Inc (LYRA) News

Lyra Therapeutics (LYRA)

Lyra Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LYRA
DateTimeSourceHeadlineSymbolCompany
21/05/202414:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LYRALyra Therapeutics Inc
21/05/202414:14GlobeNewswire Inc.Lyra Therapeutics Announces Cost-Cutting Measures to Preserve CapitalNASDAQ:LYRALyra Therapeutics Inc
06/05/202412:59GlobeNewswire Inc.Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic RhinosinusitisNASDAQ:LYRALyra Therapeutics Inc
30/04/202421:04GlobeNewswire Inc.Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:LYRALyra Therapeutics Inc
26/04/202421:51GlobeNewswire Inc.Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:LYRALyra Therapeutics Inc
21/03/202420:01GlobeNewswire Inc.Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:LYRALyra Therapeutics Inc
01/03/202421:01GlobeNewswire Inc.Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:LYRALyra Therapeutics Inc
15/02/202414:18Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LYRALyra Therapeutics Inc
15/02/202401:35Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LYRALyra Therapeutics Inc
14/02/202423:18Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LYRALyra Therapeutics Inc
14/02/202421:51Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LYRALyra Therapeutics Inc
14/02/202421:18Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LYRALyra Therapeutics Inc
13/02/202421:34Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:LYRALyra Therapeutics Inc
01/02/202421:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LYRALyra Therapeutics Inc
01/02/202421:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LYRALyra Therapeutics Inc
08/01/202411:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LYRALyra Therapeutics Inc
28/12/202311:40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LYRALyra Therapeutics Inc
18/12/202321:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LYRALyra Therapeutics Inc
16/11/202322:00Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:LYRALyra Therapeutics Inc
13/11/202322:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LYRALyra Therapeutics Inc
07/11/202321:23Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LYRALyra Therapeutics Inc
07/11/202321:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LYRALyra Therapeutics Inc
07/11/202321:01GlobeNewswire Inc.Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:LYRALyra Therapeutics Inc
07/11/202312:00GlobeNewswire Inc.Lyra Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:LYRALyra Therapeutics Inc
16/10/202312:00GlobeNewswire Inc.Lyra Therapeutics Announces Appointment of Ronan O’Brien as Chief Legal OfficerNASDAQ:LYRALyra Therapeutics Inc
12/09/202321:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LYRALyra Therapeutics Inc
12/09/202312:00GlobeNewswire Inc.Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus SurgeryNASDAQ:LYRALyra Therapeutics Inc
06/09/202313:00GlobeNewswire Inc.Lyra Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:LYRALyra Therapeutics Inc
01/09/202321:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LYRALyra Therapeutics Inc
01/09/202321:01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:LYRALyra Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:LYRA

Your Recent History

NASDAQ
ASUR
Asure Software
COIN
DINETH
Dinero
ASX
MET
Mt Isa Metals
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved